Literature DB >> 19404054

Outcomes of surgery alone for lower rectal cancer with and without pelvic sidewall dissection.

Hirotoshi Kobayashi1, Hidetaka Mochizuki, Tomoyuki Kato, Takeo Mori, Shingo Kameoka, Kazuo Shirouzu, Kenichi Sugihara.   

Abstract

PURPOSE: The goal of this retrospective multicenter study was to investigate the efficacy of pelvic sidewall dissection for lower rectal cancer.
METHODS: Data from 1,272 consecutive patients who underwent total mesorectal excision for lower rectal cancer in 12 institutions from 1991 through 1998 were reviewed. The rates of local recurrence and survival in patients with pelvic sidewall dissection were compared with those without pelvic sidewall dissection. Logistic regression analysis was used to determine independent risk factors for lymph node metastasis and local recurrence, and the Cox proportional hazards model was used to determine independent prognostic factors.
RESULTS: Of the 1,272 patients, 784 underwent pelvic sidewall dissection. Among them, 117 patients (14.9 percent) had lateral pelvic lymph node metastasis. Risk factors for lateral pelvic lymph node metastasis included female gender, tumor not well-differentiated adenocarcinoma, and perirectal lymph node metastasis. Lateral pelvic and perirectal lymph node metastases were independent risk factors for local recurrence. The Cox proportional hazard model showed age, grade of histology, invasion depth of the tumor, perirectal lymph node metastasis, and lateral pelvic lymph node metastasis to be independent prognostic factors. No significant differences between patients with and those without pelvic sidewall dissection were seen regarding rates of local recurrence (10.5 percent vs. 7.4 percent) or five-year overall survival (75.8 percent vs. 79.5 percent). Although the proportion of patients with advanced stages of disease was greater in patients who had pelvic sidewall dissection, no differences between the two groups were seen in local recurrence even when tumor category was taken into account. However, lack of pelvic sidewall dissection was a predictor of poor prognosis.
CONCLUSIONS: Although pelvic sidewall dissection does not appear to confer overall benefits regarding local recurrence or survival, the effectiveness of pelvic sidewall dissection in specific patient groups remains uncertain. A randomized controlled study is necessary to clarify this issue.

Entities:  

Mesh:

Year:  2009        PMID: 19404054     DOI: 10.1007/DCR.0b013e3181a1d994

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN: 0012-3706            Impact factor:   4.585


  45 in total

1.  Is lateral pelvic lymph node dissection no longer necessary for low rectal cancer after neoadjuvant therapy and TME to reduce local recurrence?

Authors:  Takashi Akiyoshi; Toshiaki Watanabe; Masashi Ueno
Journal:  J Gastrointest Surg       Date:  2012-07-06       Impact factor: 3.452

2.  S122: impact of fluorescence and 3D images to completeness of lateral pelvic node dissection.

Authors:  Hye Jin Kim; Gyu-Seog Choi; Jun Seok Park; Soo Yeun Park; Seung Hyun Cho; An Na Seo; Ghuil Suk Yoon
Journal:  Surg Endosc       Date:  2019-05-28       Impact factor: 4.584

3.  Survival benefit of lateral lymph node dissection according to the region of involvement and the number of lateral lymph nodes involved.

Authors:  Shozo Yokoyama; Katsunari Takifuji; Tsukasa Hotta; Kenji Matsuda; Takashi Watanabe; Yasuyuki Mitani; Junji Ieda; Hiroki Yamaue
Journal:  Surg Today       Date:  2013-12-27       Impact factor: 2.549

4.  Lateral lymph node dissection for lower rectal cancer.

Authors:  T Nakamura; M Watanabe
Journal:  World J Surg       Date:  2013-08       Impact factor: 3.352

5.  Incidence and Predictive Model for Lateral Pelvic Lymph Node Metastasis in Lower Rectal Cancer.

Authors:  Kapil Dev; K V Veerenderkumar; Swamyvelu Krishnamurthy
Journal:  Indian J Surg Oncol       Date:  2018-02-04

6.  Therapeutic effects and limitations of chemoradiotherapy in advanced lower rectal cancer focusing on T4b.

Authors:  Kosuke Ozaki; Kazushige Kawai; Hiroaki Nozawa; Kazuhito Sasaki; Koji Murono; Shigenobu Emoto; Yuuki Iida; Hiroaki Ishii; Yuichiro Yokoyama; Hiroyuki Anzai; Hirofumi Sonoda; Kenichi Sugihara; Soichiro Ishihara
Journal:  Int J Colorectal Dis       Date:  2021-05-03       Impact factor: 2.571

Review 7.  Recent advances in robotic surgery for rectal cancer.

Authors:  Soichiro Ishihara; Kensuke Otani; Koji Yasuda; Takeshi Nishikawa; Junichiro Tanaka; Toshiaki Tanaka; Tomomichi Kiyomatsu; Keisuke Hata; Kazushige Kawai; Hiroaki Nozawa; Shinsuke Kazama; Hironori Yamaguchi; Eiji Sunami; Joji Kitayama; Toshiaki Watanabe
Journal:  Int J Clin Oncol       Date:  2015-06-10       Impact factor: 3.402

8.  Deformation of the Pelvic Arteries Caused by Pneumoperitoneum and Postural Changes in an Animal Model.

Authors:  Hidemichi Kiyomatsu; Lei Ma; Junchen Wang; Tomomichi Kiyomatsu; Hiroyuki Tsukihara; Etsuko Kobayashi; Ichiro Sakuma; Souichiro Ishihara
Journal:  In Vivo       Date:  2021 Jan-Feb       Impact factor: 2.155

9.  Oncological benefit of lateral pelvic lymph node dissection for rectal cancer treated without preoperative chemoradiotherapy: a multicenter retrospective study using propensity score analysis.

Authors:  Soichiro Ishihara; Yukihide Kanemitsu; Koji Murono; Kensuke Otani; Koji Yasuda; Takeshi Nishikawa; Toshiaki Tanaka; Junichiro Tanaka; Tomomichi Kiyomatsu; Kazushige Kawai; Keisuke Hata; Hioaki Nozawa; Shinsuke Kazama; Hironori Yamaguchi; Eiji Sunami; Kenichi Sugihara; Toshiaki Watanabe
Journal:  Int J Colorectal Dis       Date:  2016-05-30       Impact factor: 2.571

10.  Stereotactic/hypofractionated body radiation therapy as an effective treatment for lymph node metastases from colorectal cancer: an institutional retrospective analysis.

Authors:  Ciro Franzese; Antonella Fogliata; Tiziana Comito; Angelo Tozzi; Cristina Iftode; Elena Clerici; Davide Franceschini; Pierina Navarria; Anna Maria Ascolese; Lucia Di Brina; Fiorenza De Rose; Giuseppe R D'Agostino; Luca Cozzi; Marta Scorsetti
Journal:  Br J Radiol       Date:  2017-10-03       Impact factor: 3.039

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.